scholarly journals STUDIES ON IMMUNITY TO PNEUMOCOCCUS MUCOSUS (TYPE III)

1927 ◽  
Vol 46 (2) ◽  
pp. 343-356 ◽  
Author(s):  
William S. Tillett
Keyword(s):  
Virulent Strain ◽  
Type I ◽  
Experimental Conditions ◽  
Type Iii ◽  
Active Immunity

1. Immunization of rabbits with Type III pneumococci is effective in producing active immunity against infection with a virulent strain of the homologous organism. 2. Immunization of rabbits with Type I or II pneumococci, and with R forms derived from any of the fixed types, is equally effective in producing active immunity against Type III infection. 3. Immunization of rabbits with nucleoprotein or with desoxycholate solutions of heterologous pneumococci, under the experimental conditions described, appears to be ineffective in producing active immunity against Type III infection.

scholarly journals ACTIVE AND PASSIVE IMMUNITY TO PNEUMOCOCCUS INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R PNEUMOCOCCI

1928 ◽  
Vol 48 (6) ◽  
pp. 791-804 ◽  
Author(s):  
William S. Tillett
Keyword(s):  
Whole Blood ◽  
Acquired Resistance ◽  
Underlying Mechanism ◽  
Immune Serum ◽  
Type I ◽  
Experimental Conditions ◽  
Passive Protection ◽  
Type Iii ◽  
Intravenous Injections ◽  
Infecting Organisms

1. Rabbits, vaccinated by repeated intravenous injections of suspensions of heat-killed R pneumococci, acquire a marked degree of active immunity to infection with the virulent S forms of Pneumococcus Types I and II. Previously (1) it was shown that the immunization of rabbits with R cells induces active resistance to Type III infection. This immunity is effective when the infecting organisms are injected either intravenously, intraperitoneally, or intradermally. 2. Whole citrated blood or serum of rabbits immunized with R pneumococci, under the experimental conditions described, is capable of passively protecting normal rabbits against Type I and Type III infection. Whole blood appears to be more effective than an equivalent amount of serum. 3. Passive protection of mice by the use of whole blood or serum of the immune rabbits has been entirely ineffectual. This is in striking contrast to the results obtained with type-specific immune serum. 4. This form of acquired resistance to pneumococcus infection, elicited by R organisms which are devoid of type specificity, and exemplified in animals whose sera possess no demonstrable type-specific antibodies, has many characteristics strongly suggesting that the underlying mechanism differs from that concerned in type-specific immunity.

scholarly journals REACTIONS OF RABBITS TO INTRACUTANEOUS INJECTIONS OF PNEUMOCOCCI AND THEIR PRODUCTS

1930 ◽  
Vol 51 (3) ◽  
pp. 449-462 ◽  
Author(s):  
Louis A. Julianelle
Keyword(s):  
High Titre ◽  
Type I ◽  
Specific Antibodies ◽  
Type Iii ◽  
Active Immunity ◽  
Protective Antibodies ◽  
Derivatives Of

1. Injection of suspensions of heat-killed pneumococci into the skin of rabbits is followed by an active immunity which is effective against intravenous infection by homologous and heterologous types of Pneumococcus. 2. This form of active immunity may be induced by the injection of S or R strains of Pneumococcus. 3. Intracutaneous immunization with soluble derivatives of Pneumococcus does not induce active immunity to infection. 4. The sera of seventy-nine per cent of the rabbits immunized to Type I Pneumococcus by intracutaneous injections afforded no protection to mice against infection with pneumococci. 5. None of the sera of rabbits intracutaneously immunized to the type-specific Type III (S) pneumococci, to R cells, or to soluble derivatives of Pneumococcus protected white mice against infection. 6. The sera of rabbits immunized first intracutaneously and subsequently intravenously possess a high titre of protective antibodies. 7. It may be concluded that when type-specific pneumococci are injected into the skin they lose the property of stimulating an active immunity of a specific type and of stimulating the production of type-specific antibodies, but they act just as do the degraded or R forms, causing the animals to become resistant to infection with pneumococci of all types without the development of any type-specific antibodies in the serum.

scholarly journals ORAL IMMUNIZATION AGAINST PNEUMOCOCCUS TYPES II AND III AND THE NORMAL VARIATION IN RESISTANCE TO THESE TYPES AMONG RATS

1931 ◽  
Vol 54 (6) ◽  
pp. 875-898 ◽  
Author(s):  
Victor Ross
Keyword(s):  
Bile Salt ◽  
Oral Immunization ◽  
Type I ◽  
Type Ii ◽  
Normal Variation ◽  
Type Iii ◽  
Active Immunity ◽  
The Dead ◽  
Partial Immunity

1. Considerable variation in the resistance of different rats toward Type II pneumococcus has been demonstrated. In general, older rats survive much greater doses than young ones, illustrating the acquisition of a natural partial immunity. The same is true for Type III but the immunity appears somewhat later in life and does not reach the same height. 2. An active immunity can be created against Types II and III in rats by feeding the dead organisms or the Berkefeld filtrate of the bile salt-dissolved cells. This immunity resembles that obtained against Type I in several respects.

scholarly journals CHEMOIMMUNOLOGICAL STUDIES ON THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS

1933 ◽  
Vol 58 (6) ◽  
pp. 731-755 ◽  
Author(s):  
Oswald T. Avery ◽  
Walther F. Goebel
Keyword(s):  
Chemical Form ◽  
Type I ◽  
Bacterial Cells ◽  
Subsequent Infection ◽  
Experimental Conditions ◽  
Intravenous Injections ◽  
Active Immunity ◽  
Specific Substance ◽  
Protective Antibodies ◽  
Pneumococcus Type

The soluble specific substance of Pneumococcus Type I has been chemically isolated from the bacterial cells and from autolyzed cultures as an acetyl polysaccharide. So far as could be determined by the methods employed, the acetyl polysaccharide in highly purified form absorbs from Type I antipneumococcus serum all demonstrable type-specific precipitins, agglutinins and protective antibodies. Mice injected intraperitoneally with minute quantities of the acetyl polysaccharide develop active immunity to subsequent infection with Pneumococcus Type I. The immunity thus induced is type-specific. In several instances purpura has been observed in mice following the injection of larger amounts of the acetyl polysaccharide. Under the experimental conditions of this study, no type-specific precipitins, agglutinins or protective antibodies were demonstrable in the serum of rabbits following repeated intravenous injections of the Type I acetyl polysaccharide. The treated rabbits were not immune to subsequent infection with Pnemnococcus Type I. The acetyl polysaccharide is readily converted into its deacetylated derivative by treatment with dilute alkali. The chemical and immunological properties of the deacetylated polysaccharide are identical with those of the soluble specific substance in the chemical form in which it was originally isolated; the deacetylated form of the specific carbohydrate is non-antigenic, does not produce purpura in mice, and only incompletely absorbs the type-specific antibodies from Type I antipneumococcus serum. The immunological significance of the acetyl polysaccharide and its possible relationship to the specific substances isolated from Pneumococcus Type I by other workers are discussed.

Methionine-Specific Staining of Collagen

1982 ◽  
Vol 40 ◽  
pp. 294-295
Author(s):  
E.M. Kuhn ◽  
K.D. Marenus ◽  
M. Beer
Keyword(s):  
Amino Acids ◽  
Collagen Fibers ◽  
Type Iii Collagen ◽  
Type I ◽  
Electron Microscopic ◽  
Good Correspondence ◽  
Specific Staining ◽  
Type Iii ◽  
Different Types ◽  
Sulfur Containing

Fibers composed of different types of collagen cannot be differentiated by conventional electron microscopic stains. We are developing staining procedures aimed at identifying collagen fibers of different types.Pt(Gly-L-Met)Cl binds specifically to sulfur-containing amino acids. Different collagens have methionine (met) residues at somewhat different positions. A good correspondence has been reported between known met positions and Pt(GLM) bands in rat Type I SLS (collagen aggregates in which molecules lie adjacent to each other in exact register). We have confirmed this relationship in Type III collagen SLS (Fig. 1).

Labelling of non-A, non-B hepatitis infected chimpanzee hepatocytes with nuclease-gold conjugates

1984 ◽  
Vol 42 ◽  
pp. 250-251
Author(s):  
G. D. Gagne ◽  
M. F. Miller ◽  
D. A. Peterson
Keyword(s):  
Endoplasmic Reticulum ◽  
Experimental Infection ◽  
Uranyl Acetate ◽  
Type I ◽  
Cellular Injury ◽  
Type Ii ◽  
Tubular Structures ◽  
Type Iii ◽  
Type Iv ◽  
Infected Chimpanzee

Experimental infection of chimpanzees with non-A, non-B hepatitis (NANB) or with delta agent hepatitis results in the appearance of characteristic cytoplasmic alterations in the hepatocytes. These alterations include spongelike inclusions (Type I), attached convoluted membranes (Type II), tubular structures (Type III), and microtubular aggregates (Type IV) (Fig. 1). Type I, II and III structures are, by association, believed to be derived from endoplasmic reticulum and may be morphogenetically related. Type IV structures are generally observed free in the cytoplasm but sometimes in the vicinity of type III structures. It is not known whether these structures are somehow involved in the replication and/or assembly of the putative NANB virus or whether they are simply nonspecific responses to cellular injury. When treated with uranyl acetate, type I, II and III structures stain intensely as if they might contain nucleic acids. If these structures do correspond to intermediates in the replication of a virus, one might expect them to contain DNA or RNA and the present study was undertaken to explore this possibility.

scholarly journals Diastolic dyssynchrony in patients with LV only fusion pacing CRT without RV lead

2021 ◽  
Vol 22 (Supplement_1) ◽  
Author(s):  
A Gurgu ◽  
L Petrescu ◽  
C Vacarescu ◽  
CT Luca ◽  
C Mornos ◽  
...  
Keyword(s):  
Lateral Wall ◽  
Positive Outcome ◽  
Type I ◽  
Exercise Tests ◽  
Type Iii ◽  
Funding Sources ◽  
End Diastolic Volume ◽  
Chamber View ◽  
Systolic And Diastolic Function

Abstract Funding Acknowledgements Type of funding sources: None. Background CRT improves both systolic and diastolic function, thus increasing cardiac output. However, less data is available concerning diastolic dyssynchrony and fusion pacing CRT. The aim of our study was to assess the outcome of LV diastolic asynchrony in a population of fusion pacing CRT without right ventricular (RV)  lead. Methods Prospective data were collected from a cohort of patients (pts) with right atrium/left ventricle leads (RA/LV CRT). Baseline and every 6 months follow-up included standard ETT and classical dyssynchrony parameter measurements. Diastolic dyssynchrony was done by offline speckle-tracking derived TDI timing assesment of the simultaneity of E" and A"  basal septal and lateral wall 4 chamber view. New parameters were introduced: E" and respectively A" time (E"T / A"T) as the time difference between E" (respectively A" ) peaks septal and lateral wall. Exercise tests, drugs optimization and device individual programmimg were systematically performed in order to maintain constant fusion and improve CRT response. Patients were divided in three groups: super-responders (SR), responders (R) and non responders (NR). Results Sixty-two pts (35 male) aged 62 ± 11 y.o. with idiopathic DCM implanted with a RA/LV CRT were analyzed: 34%SR / 61%R / 5%NR. Baseline initial characteristics: QRS 164 ± 18 ms; EF 27 ± 5.2; 29% had type III diastolic dysfunction (DD), 63% type II DD, 8% type I DD. Average follow-up was 45 ± 19 months; mean LVEF at the last follow-up was 37 ± 7.9%. The E"T decreased from 90 ± 20 ms to 25 ± 10 ms in SR with significant LV reverse remodelling (LV end-diastolic volume 193.7 ± 81 vs 243.2 ± 82 ml at baseline, p < 0.0028) and lower LV filling pressures (E/E" 13.2 ± 4.6 vs 11.4 ± 4.5, p =0.0295). DD profile improved in 65% of R with a reduction in E/A ratio (1.46 ± 5.3 vs. 0.82 ± 3.9 at baseline, p= 0.4453). Non-sudden cardiac death occurred in 3 NR pts (2%) with type III DD, severe LA volume and larger E" T /A"T (E"T> 85 msec A"T > 30 msec).  Significant cut off value calculated by ROC curve for LV diastolic dyssynchrony is E"T > 80 ms and A"T of > 25 msec. Conclusions Fusion pacing CRT without RV lead showed a positive outcome; improving LV diastolic dyssynchrony in responders and super-responders patients is obvious. Larger randomized studies are needed to define the role of diastolic asynchronism as a predictor of favorable response in fusion pacing. Abstract Figure. Typical TDI patterns in LV fusion pacing

scholarly journals Perforator preservation technologies (PPT) based on a new neuro-interventional classification in endovascular treatment of perforator involving aneurysms (piANs)

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Chen Li ◽  
Ao-Fei Liu ◽  
Han-Cheng Qiu ◽  
Xianli Lv ◽  
Ji Zhou ◽  
...  
Keyword(s):  
Endovascular Therapy ◽  
Saccular Aneurysm ◽  
Type I ◽  
Type Ii ◽  
Fusiform Aneurysm ◽  
Type Iii ◽  
Perforating Artery ◽  
Protection Technology ◽  
Perforating Arteries

Abstract Background Treatment of perforator involving aneurysm (piAN) remains a challenge to open and endovascular neurosurgeons. Our aim is to demonstrate a primary outcome of endovascular therapy for piANs with the use of perforator preservation technologies (PPT) based on a new neuro-interventional classification. Methods The piANs were classified into type I: aneurysm really arises from perforating artery, type II: saccular aneurysm involves perforating arteries arising from its neck (IIa) or dome (IIb), and type III: fusiform aneurysm involves perforating artery. Stent protection technology of PPT was applied in type I and III aneurysms, and coil-basket protection technology in type II aneurysms. An immediate outcome of aneurysmal obliteration after treatment was evaluated (satisfactory obliteration: the saccular aneurysm body is densely embolized (I), leaving a gap in the neck (IIa) or dome (IIb) where the perforating artery arising; fusiform aneurysm is repaired and has a smooth inner wall), and successful perforating artery preservation was defined as keeping the good antegrade flow of those perforators on postoperative angiography. The periprocedural complication was closely monitored, and clinical and angiographic follow-ups were performed. Results Six consecutive piANs (2 ruptured and 4 unruptured; 1 type I, 2 type IIa, 2 type IIb, and 1 type III) in 6 patients (aged from 43 to 66 years; 3 males) underwent endovascular therapy between November 2017 and July 2019. The immediate angiography after treatment showed 6 aneurysms obtained satisfactory obliteration, and all of their perforating arteries were successfully preserved. During clinical follow-up of 13–50 months, no ischemic or hemorrhagic event of the brain occurred in the 6 patients, but has one who developed ischemic event in the territory of involving perforators 4 h after operation and completely resolved within 24 h. Follow-up angiography at 3 to 10M showed patency of the parent artery and perforating arteries of treated aneurysms, with no aneurysmal recurrence. Conclusions Our perforator preservation technologies on the basis of the new neuro-interventional classification seem feasible, safe, and effective in protecting involved perforators while occluding aneurysm.

scholarly journals Intracellular and Extracellular Markers of Lethality in Osteogenesis Imperfecta: A Quantitative Proteomic Approach

2021 ◽  
Vol 22 (1) ◽  
pp. 429
Author(s):  
Luca Bini ◽  
Domitille Schvartz ◽  
Chiara Carnemolla ◽  
Roberta Besio ◽  
Nadia Garibaldi ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Type I Collagen ◽  
Type I ◽  
Tandem Mass ◽  
Type Ii ◽  
Type Iii ◽  
Bioinformatic Tools ◽  
Proteomic Approach ◽  
Fibrillin 1 ◽  
Heritable Disorder

Osteogenesis imperfecta (OI) is a heritable disorder that mainly affects the skeleton. The inheritance is mostly autosomal dominant and associated to mutations in one of the two genes, COL1A1 and COL1A2, encoding for the type I collagen α chains. According to more than 1500 described mutation sites and to outcome spanning from very mild cases to perinatal-lethality, OI is characterized by a wide genotype/phenotype heterogeneity. In order to identify common affected molecular-pathways and disease biomarkers in OI probands with different mutations and lethal or surviving phenotypes, primary fibroblasts from dominant OI patients, carrying COL1A1 or COL1A2 defects, were investigated by applying a Tandem Mass Tag labeling-Liquid Chromatography-Tandem Mass Spectrometry (TMT LC-MS/MS) proteomics approach and bioinformatic tools for comparative protein-abundance profiling. While no difference in α1 or α2 abundance was detected among lethal (type II) and not-lethal (type III) OI patients, 17 proteins, with key effects on matrix structure and organization, cell signaling, and cell and tissue development and differentiation, were significantly different between type II and type III OI patients. Among them, some non–collagenous extracellular matrix (ECM) proteins (e.g., decorin and fibrillin-1) and proteins modulating cytoskeleton (e.g., nestin and palladin) directly correlate to the severity of the disease. Their defective presence may define proband-failure in balancing aberrances related to mutant collagen.

Sign in / Sign up

Export Citation Format

Share Document